1. Home
  2. Analysis
  3. Omniscan
  4. Cefdinir

Omniscan and Cefdinir drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported only by a few people who take Omniscan and Cefdinir together.

The phase IV clinical study analyzes what interactions people who take Omniscan and Cefdinir have. It is created by eHealthMe based on reports of 5 people who take the same drugs from the FDA, and is updated regularly.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Mar, 08, 2023

5 people who take Omniscan and Cefdinir together, and have interactions are studied.

What is Omniscan?

Omniscan has active ingredients of gadodiamide. eHealthMe is studying from 6,131 Omniscan users for its effectiveness, alternative drugs and more.

What is Cefdinir?

Cefdinir has active ingredients of cefdinir. It is often used in sinusitis. eHealthMe is studying from 7,898 Cefdinir users for its effectiveness, alternative drugs and more.

Number of Omniscan and Cefdinir reports submitted per year:

Omniscan and Cefdinir drug interactions.

Common Omniscan and Cefdinir drug interactions by gender *:

female:

  1. Abdominal pain upper
  2. Cerebrovascular accident
  3. Gastric disorder
  4. Gastrooesophageal reflux disease
  5. Haemoglobin decreased
  6. Nephrogenic systemic fibrosis
  7. Oedema peripheral
  8. Pigmentation disorder
  9. Platelet count decreased
  10. Scleroderma

male:

  1. Nephrogenic systemic fibrosis
  2. Musculoskeletal stiffness
  3. Oedema peripheral
  4. Platelet count decreased
  5. Renal atrophy
  6. Renal failure
  7. Red blood cell count decreased
  8. Renal impairment
  9. Skin disorder
  10. Venous pressure increased

Common Omniscan and Cefdinir drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

  1. Abdominal pain upper
  2. Cerebrovascular accident
  3. Gastric disorder
  4. Gastrooesophageal reflux disease
  5. Haemoglobin decreased
  6. Nephrogenic systemic fibrosis
  7. Oedema peripheral
  8. Pigmentation disorder
  9. Platelet count decreased
  10. Scleroderma

60+:

  1. Nephrogenic systemic fibrosis
  2. Musculoskeletal stiffness
  3. Oedema peripheral
  4. Platelet count decreased
  5. Renal atrophy
  6. Renal failure
  7. Red blood cell count decreased
  8. Renal impairment
  9. Skin disorder
  10. Venous pressure increased

* Approximation only. Some reports may have incomplete information.

Do you take Omniscan and Cefdinir?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

Alternative drugs to, pros and cons of the 2 drugs:

Browse all drug interactions of Omniscan and Cefdinir:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Omniscan side effects:

Browse all side effects of Omniscan:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Cefdinir side effects:

Browse all side effects of Cefdinir:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Omniscan interactions:

Browse all interactions between Omniscan and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Cefdinir interactions:

Browse all interactions between Cefdinir and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on gadodiamide and cefdinir (the active ingredients of Omniscan and Cefdinir, respectively), and Omniscan and Cefdinir (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study. Patients in the study may take other drugs besides Omniscan and Cefdinir.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2023 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.